$104.72 0.00 (%) Medivation Inc - NASDAQ

Jan. 27, 2015 | 04:00 PM

Partner Headlines

  1. Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and ...

    GuruFocus | Jan. 25, 2015 | 23:19PM EST
  2. Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as ...

    GuruFocus | Jan. 22, 2015 | 11:05AM EST
  3. J&J Earnings Beat, But Sales, Guidance Miss Estimates

    IBD | Jan. 20, 2015 | 11:20AM EST
  4. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD | Jan. 15, 2015 | 11:02AM EST
  5. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  6. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market

    Benzinga | Jan. 6, 2015 | 12:21PM EST
  7. William Blair's Top BioPharmaceutical Stock Picks for Q1 2015

    GuruFocus | Dec. 23, 2014 | 14:47PM EST
  8. Newly Profitable Medivation Riding High On Drug Sales

    IBD | Nov. 28, 2014 | 17:20PM EST
  9. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD | Nov. 24, 2014 | 14:58PM EST
  10. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga | Nov. 7, 2014 | 15:30PM EST
  11. Medivation Hits High After Q3 Earnings Beat

    IBD | Nov. 7, 2014 | 11:15AM EST
  12. Medivation Hits High After Q3 Earnings Beat

    IBD | Nov. 7, 2014 | 11:15AM EST
  13. Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, ...

    GuruFocus | Oct. 31, 2014 | 01:02AM EST
  14. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD | Oct. 14, 2014 | 11:54AM EST
  15. Consider Medivation for Your Portfolio

    FoxBusiness | Oct. 6, 2014 | 13:31PM EST
  16. Benzinga's Top Downgrades

    Benzinga | Sep. 24, 2014 | 08:52AM EST
  17. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga | Sep. 24, 2014 | 08:38AM EST
  18. These 3 Biotech Stocks Just Hit New Highs

    Benzinga | Sep. 22, 2014 | 13:31PM EST
  19. Fast Money Halftime Report Final Trade From September 12

    Benzinga | Sep. 12, 2014 | 22:04PM EST
  20. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD | Sep. 11, 2014 | 17:41PM EST
  21. Stifel Raises Medivation Inc Price Target

    Benzinga | Sep. 11, 2014 | 08:32AM EST
  22. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 10, 2014 | 10:05AM EST
  23. A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

    GuruFocus | Aug. 15, 2014 | 12:18PM EST
  24. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD | Aug. 8, 2014 | 11:55AM EST
  25. Benzinga's Volume Movers

    Benzinga | Aug. 8, 2014 | 10:32AM EST
  26. Medivation Announces Change in Executive Management Team; Dawn Svoronos To Chief Commercial Officer

    Benzinga | Jul. 10, 2014 | 16:11PM EST
  27. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga | Jul. 3, 2014 | 12:26PM EST
  28. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga | Jul. 2, 2014 | 10:28AM EST
  29. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer Survey

    Benzinga | Jun. 23, 2014 | 09:33AM EST
  30. Benzinga's Top Upgrades

    Benzinga | Jun. 19, 2014 | 07:46AM EST
  31. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga | May. 6, 2014 | 07:29AM EST
  32. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as Urologist Uptake is Unclear

    Benzinga | Apr. 16, 2014 | 09:45AM EST
  33. Morning Market Movers

    Benzinga | Apr. 1, 2014 | 09:43AM EST
  34. Stocks To Watch For April 1, 2014

    Benzinga | Apr. 1, 2014 | 04:22AM EST
  35. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

    Benzinga | Mar. 26, 2014 | 07:56AM EST
  36. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment

    Benzinga | Mar. 24, 2014 | 16:11PM EST
  37. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Mar. 12, 2014 | 10:01AM EST
  38. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga | Feb. 28, 2014 | 16:53PM EST
  39. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

    Benzinga | Feb. 28, 2014 | 10:40AM EST
  40. Benzinga's Top #PreMarket Losers

    Benzinga | Feb. 28, 2014 | 08:15AM EST
  41. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts | Feb. 12, 2014 | 09:31AM EST
  42. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga | Jan. 29, 2014 | 15:31PM EST
  43. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro Shares Rise

    Benzinga | Jan. 29, 2014 | 12:35PM EST
  44. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga | Jan. 29, 2014 | 11:44AM EST
  45. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts Upbeat Profit

    Benzinga | Jan. 29, 2014 | 10:22AM EST
  46. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 29, 2014 | 10:07AM EST
  47. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 29, 2014 | 08:09AM EST
  48. Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide

    Benzinga | Jan. 28, 2014 | 17:03PM EST
  49. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line 3Q 2013 Financial Results

    Benzinga | Nov. 13, 2013 | 10:54AM EST
  50. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide Met Co-Primary Endpoints

    Benzinga | Oct. 22, 2013 | 07:46AM EST
Trading Center